Shattuck Labs reported third-quarter 2026 results alongside progress in its experimental inflammatory-disease treatments. The main development is that its lead drug, SL-325, has entered a mid-stage trial for Crohn’s disease, with a second Phase 2 study in hidradenitis suppurativa planned to begin by year-end.
The release also highlighted early work on SL-846, a separate antibody candidate. The supplied results announcement does not include financial figures.
Key details
- Crohn’s disease trial underway: Shattuck has started RECEPTIVE-CD1, a Phase 2b trial of SL-325. The company expects to report 12-week induction results in the first half of 2028.
- Second SL-325 study planned: The company expects to begin RECEPTIVE-HS1, a Phase 2 trial in hidradenitis suppurativa, in the fourth quarter of 2026.
- SL-325’s early clinical profile: Shattuck said Phase 1 results showed favorable safety and tolerability, an anti-drug antibody rate of 3.7%, and sustained blocking of TL1A binding to DR3. The company says the durability may support maintenance dosing as infrequently as once every three months.
- How the studies fit Shattuck’s strategy: SL-325 is designed to block DR3, a target involved in inflammatory and immune-mediated diseases. Shattuck says its Crohn’s and hidradenitis studies will allow comparisons with the TL1A antibody class and help assess whether that class’s potential immunogenicity limits treatment efficacy.
- SL-846 remains in development: Shattuck presented preclinical findings for SL-846 at UEG Week 2026, including results from a chronic toxicology study in non-human primates. The candidate is designed to block both DR3 and the IL-23 receptor. The company expects to share initial Phase 1 data in 2027.
Plain-English implications
Shattuck is moving SL-325 into Phase 2 testing in two diseases, shifting the program beyond early safety testing toward evaluations of treatment effects. The next major data point identified by the company is the Crohn’s trial’s 12-week induction readout, expected in the first half of 2028. SL-846 is at an earlier stage, with human data still expected in 2027.